Key Highlights

  • Lyell Immunopharma (NASDAQ:LYEL) traded at USD 14.28, up 32.59% intraday on November 4, 2026, on 166.58 thousand shares, per intraday market data.
  • The company agreed to sell 7,428,040 shares at USD 10.77, the November 3 close, for about USD 80 million gross, with a 9:02 a.m. ET release naming ARCH, Adage, Caligan and RTW.
  • Cash is expected to fund operations into 2028, through pivotal ronde-cel data in mid-2027 and a planned BLA submission in the second half of 2027.
  • A same-day release reported a 91% response rate and 77% complete response rate in 44 evaluable third-line patients, company-reported ahead of the December 2026 ASH meeting.

What Moved Lyell Immunopharma During Trading (up USD 3.51, 32.59%)

Lyell Immunopharma (NASDAQ:LYEL) was up USD 3.51, or 32.59%, at USD 14.28 during trading on November 4, 2026. That implies a November 3 close of about USD 10.77 (calculated), which matches the Placement price in the company release. At 9:02 a.m. ET the company announced a private placement of 7,428,040 common shares for about USD 80 million gross, expected to close on or about November 4, 2026. Goldman Sachs and Leerink Partners acted as placement agents. Investors included ARCH Venture Partners, Adage Capital Management, Caligan Partners, RTW Investments, a Mutual fund and other institutions. Priced at the prior close, the deal carried no discount.

The Clinical Update and Pipeline

A separate company release on November 4, 2026 highlighted updated data for ronde-cel, a CD19/CD20 CAR T cell therapy for large B-cell lymphoma, to be shown at the 68th ASH Annual Meeting on December 12 to 15, 2026. In the third-line PiNACLE cohort, 58 patients were treated by the June 18, 2026 cutoff and 44 were evaluable at Day 84. The overall response rate was 91% (40 of 44) and the complete response rate 77% (34 of 44). No grade 3 or higher cytokine release syndrome occurred, and grade 3 or higher neurotoxicity was 9%. These are company-reported, single-arm figures not independently verified. The pivotal dataset is expected in mid-2027 and a BLA submission in the second half of 2027.

Dilution, Funding and Risk

Selling new shares raises cash but spreads ownership across more shares. If the intraday market Capitalization of USD 349.93 million is accurate, it implies about 24.5 million shares at USD 14.28, so 7.43 million new shares would be roughly 30% more (simple arithmetic on published numbers, not confirmed). The shares are unregistered and carry resale registration rights on Form S-3, so a later registration could add supply. Proceeds fund ronde-cel pivotal trials, LYL273 for colorectal cancer and working capital. Volume of 166.58 thousand shares is modest, so a small number of trades can move the price and quoted gains can reverse. The company is still pre-revenue, with a BLA submission about two years away and no approval assured.

Where Things Stand

Lyell Immunopharma (NASDAQ:LYEL) is up 32.59% because an USD 80 million placement at USD 10.77 from specialist healthcare investors arrived alongside updated ronde-cel data showing a 91% response rate, and because the cash extends the runway into 2028. The data are company-reported and from a single-arm cohort, and the new shares add dilution. Next markers are the ASH presentations on December 12 and December 14, 2026, the placement closing, the Form S-3 resale registration and the mid-2027 pivotal dataset.